Evidence map›Paper›PMID 42665428›Full record

ArticleIn vivo (Athens, Greece)

Pneumonitis in Older Patients With Non-squamous Non-small Cell Lung Cancer Treated With Pembrolizumab and Pemetrexed.

Yoshihito Kogure, Hiroya Hashimoto, Haruko Daga, Yasuhiro Goto, Tadaaki Yamada, Tomoki Kimura, Satoru Miura, Hirotoshi Yasui, Nobuyuki Yamamoto, Hideo Saka and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yoshihito KogureDepartment of Respiratory Medicine, NHO Nagoya Medical Center, Nagoya, Japan; yosh.kogure@gmail.com.
Hiroya HashimotoClinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
Haruko DagaDepartment of Medical Oncology, Osaka City General Hospital, Osaka, Japan.
Yasuhiro GotoDepartment of Respiratory Medicine, Fujita Health University, Toyoake, Japan.
Tadaaki YamadaDepartment of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Tomoki KimuraDepartment of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan.
Satoru MiuraDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
Hirotoshi YasuiDepartment of Respiratory Medicine, Toyohashi Municipal Hospital, Toyohashi, Japan.
Nobuyuki YamamotoDepartment of Pulmonary Medicine and Medical Oncology, Wakayama Medical University, Wakayama, Japan.
Hideo SakaDepartment of Respiratory Medicine, Matsunami General Hospital, Kasamatsu, Japan.
Masashi KondoDepartment of Respiratory Medicine, Fujita Health University, Toyoake, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimPembrolizumab combined with pemetrexed is efficacious in older patients with metastatic non-squamous non-small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score (TPS) of <50%. However, treatment-related pneumonitis is concerning, and its impact on clinical outcomes is not fully understood. In this study, we examined the effect of pneumonitis on treatment efficacy and survival in the CJLSG1901 study, with a focus on differences in baseline patient characteristics. PATIENTS AND

methodsSubgroup analyses were performed to explore the efficacy and safety of pembrolizumab plus pemetrexed in older patients with metastatic non-squamous NSCLC, focusing on whether pneumonitis developed after treatment initiation.

resultsOf the 48 patients included, five and four patients developed grade 1-2 and grade 3 pneumonitis, respectively. The pneumonitis group was predominantly male; postoperative recurrence was nearly twice as common in the group. Patients with pneumonitis received fewer treatment cycles. The objective response rates were 44.4% and 35.9% in the pneumonitis and non-pneumonitis groups, respectively. The median progression-free survival was shorter in the former. In contrast, the median overall survival was comparable between the groups.

conclusionAlthough patients with pneumonitis had numerically higher response rates, their survival outcomes were comparable to those of patients without pneumonitis.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsPneumoniaAgedAged, 80 and overAntibodies, Monoclonal, HumanizedFemaleHumansMaleNeoplasm StagingPemetrexedTreatment OutcomeAntibodies, Monoclonal, HumanizedpembrolizumabPemetrexednon-squamous non-small cell lung cancerolder patientspembrolizumabpemetrexedPneumonitis

Identifiers

PMID42665428
PMCPMC13531136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.